FREE NEJM E-TOC    HOME   |   SUBSCRIBE   |   CURRENT ISSUE   |   PAST ISSUES   |   COLLECTIONS   |   Search Term  Advanced Search

Sign in | Get NEJM's E-Mail Table of Contents — Free | Subscribe

Previous Volume 346:1468-1474 May 9, 2002 Number 19 Next

	Since this article has no abstract, we have provided an extract of the first 100 words of the full text and any section headings.

	Full Text PDF PDA Full Text Purchase this article Letters Add to Personal Archive Add to Citation Manager Notify a Friend E-mail When Cited PubMed Citation

This Journal feature begins with a case vignette highlighting a common clinical problem. Evidence supporting various strategies is then presented, followed by a review of formal guidelines, when they exist. The article ends with the author's clinical recommendations.

A 45-year-old man with a strong family history of premature heart disease has no symptoms of coronary disease and has a normal electrocardiogram. A fasting lipid analysis reveals a total cholesterol level of 225 mg per deciliter (5.8 mmol per liter), a high-density lipoprotein cholesterol level of 35 mg per deciliter (0.9 mmol per liter), a triglyceride level of 150 mg per . . . [Full Text of this Article]

The Clinical Problem

Strategies and Evidence

Observational Studies

Randomized Trials

Areas of Uncertainty

Aspirin Dose

Benefits in Specific Subgroups

Other Benefits

Aspirin Resistance

Dual Antiplatelet Therapy

Guidelines

Conclusions and Recommendations

Source Information

From the Department of Cardiovascular Medicine, Cleveland Clinic Foundation, Cleveland.

Address reprint requests to Dr. Lauer at the Department of Cardiovascular Medicine, Desk F25, Cleveland Clinic Foundation, 9500 Euclid Ave., Cleveland, OH 44195, or at lauerm@ccf.org.

References

Related Letters:

Aspirin for the Primary Prevention of Coronary Events
Mehta J.L., Mascitelli L., Pezzetta F., Lauer M. S.
Extract | Full Text | PDF  
N Engl J Med 2002; 347:948, Sep 19, 2002. Correspondence

This article has been cited by other articles:

• Leshno, M., Moshkowitz, M., Arber, N. (2008). Aspirin is Clinically Effective in Chemoprevention of Colorectal Neoplasia: Point. Cancer Epidemiol. Biomarkers Prev. 17: 1558-1561 [Full Text]  
• MADHWAL, S., LINCOFF, A. M., ROLSTON, D. D.K. (2008). Q: Should patients on long-term warfarin take aspirin for heart disease?. Cleveland Clinic Journal of Medicine 75: 206-208 [Full Text]  
• Patrono, C., Rocca, B. (2008). Aspirin: Promise and Resistance in the New Millennium. Arterioscler. Thromb. Vasc. Bio. 28: s25-s32 [Abstract] [Full Text]  
• Lauer, M. S. (2007). Primary Prevention of Atherosclerotic Cardiovascular Disease: The High Public Burden of Low Individual Risk. JAMA 297: 1376-1378 [Full Text]  
• Michos, E. D., Ardehali, R., Blumenthal, R. S., Lange, R. A., Ardehali, H. (2006). Aspirin and Clopidogrel Resistance. Mayo Clin Proc. 81: 518-526 [Abstract] [Full Text]  
• Jermany, J., Branson, J., Schmouder, R., Guillaume, M., Rordorf, C. (2005). Lumiracoxib Does Not Affect the Ex Vivo Antiplatelet Aggregation Activity of Low-Dose Aspirin in Healthy Subjects. J Clin Pharmacol 45: 1172-1178 [Abstract] [Full Text]  
• Campbell, P. J., Green, A. R. (2005). Management of Polycythemia Vera and Essential Thrombocythemia. ASH Education Book 2005: 201-208 [Abstract] [Full Text]  
• Hur, C., Simon, L. S, Gazelle, G S. (2005). Analysis of Aspirin-Associated Risks in Healthy Individuals. The Annals of Pharmacotherapy 39: 51-57 [Abstract] [Full Text]  
• Gill, T. M., Allore, H. G., Holford, T. R., Guo, Z. (2004). Hospitalization, Restricted Activity, and the Development of Disability Among Older Persons. JAMA 292: 2115-2124 [Abstract] [Full Text]  
• Wiggins, B. S., Spinler, S. (2004). Antiplatelet and Antithrombin Therapy for Early Management of Acute Coronary Syndromes. Journal of Pharmacy Practice 17: 347-369 [Abstract]  
• Aktas, M. K., Ozduran, V., Pothier, C. E., Lang, R., Lauer, M. S. (2004). Global Risk Scores and Exercise Testing for Predicting All-Cause Mortality in a Preventive Medicine Program. JAMA 292: 1462-1468 [Abstract] [Full Text]  
• Patrono, C., Coller, B., FitzGerald, G. A., Hirsh, J., Roth, G. (2004). Platelet-Active Drugs: The Relationships Among Dose, Effectiveness, and Side Effects: The Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy. Chest 126: 234S-264S [Abstract] [Full Text]  
• Cox, E. R., Frisse, M., Behm, A., Fairman, K. A. (2004). Over-the-Counter Pain Reliever and Aspirin Use Within a Sample of Long-term Cyclooxygenase 2 Users. Arch Intern Med 164: 1243-1246 [Full Text]  
• Wajed, J., Ahmad, Y., Durrington, P. N., Bruce, I. N. (2004). Prevention of cardiovascular disease in systemic lupus erythematosus--proposed guidelines for risk factor management. Rheumatology (Oxford) 43: 7-12 [Full Text]  
• Kimmel, S. E, Strom, B. L (2003). Giving aspirin and ibuprofen after myocardial infarction. BMJ 327: 1298-1299 [Full Text]  
• Sacco, M., Pellegrini, F., Roncaglioni, M. C., Avanzini, F., Tognoni, G., Nicolucci, A. (2003). Primary Prevention of Cardiovascular Events With Low-Dose Aspirin and Vitamin E in Type 2 Diabetic Patients: Results of the Primary Prevention Project (PPP) trial. Diabetes Care 26: 3264-3272 [Abstract] [Full Text]  
• Hawk, E T, Viner, J L (2003). Aspirin: still learning about the wonder drug. Gut 52: 1535-1536 [Full Text]  
• Dornbrook-Lavender, K. A, Pieper, J. A, Roth, M. T (2003). Primary Prevention of Coronary Heart Disease in the Elderly. The Annals of Pharmacotherapy 37: 1654-1663 [Abstract] [Full Text]  
• Balk, E. M., Lau, J., Goudas, L. C., Jordan, H. S., Kupelnick, B., Kim, L. U., Karas, R. H. (2003). Effects of Statins on Nonlipid Serum Markers Associated with Cardiovascular Disease: A Systematic Review. ANN INTERN MED 139: 670-682 [Abstract] [Full Text]  
• Zimmerman, M. A., Selzman, C. H., Cothren, C., Sorensen, A. C., Raeburn, C. D., Harken, A. H. (2003). Diagnostic Implications of C-Reactive Protein. Arch Surg 138: 220-224 [Abstract] [Full Text]  
• Davi, G., Guagnano, M. T., Ciabattoni, G., Basili, S., Falco, A., Marinopiccoli, M., Nutini, M., Sensi, S., Patrono, C. (2002). Platelet Activation in Obese Women: Role of Inflammation and Oxidant Stress. JAMA 288: 2008-2014 [Abstract] [Full Text]  
• Mehta, J.L., Mascitelli, L., Pezzetta, F., Lauer, M. S. (2002). Aspirin for the Primary Prevention of Coronary Events. NEJM 347: 948-948 [Full Text]  
• Petitti, D. B. (2002). Hormone Replacement Therapy for Prevention: More Evidence, More Pessimism. JAMA 288: 99-101 [Full Text]